000			03163nam a22003015i 4500
001			402914
003			ES-MaUEC
005			20240528105942.0
007			cr nn 008mamaa
008			240104s2023 sz | o |||| 0|eng d
020			_a9783031336027
024	7		_a10.1007/978-3-031-33602-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC254-282 _b2023 EB
245	0	0	_aBreast Cancer Research and Treatment : _bInnovative Concepts _cedited by Ouissam Al Jarroudi, Khalid El Bairi, Giuseppe Curigliano
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCancer Treatment and Research _x2509-8497 ; _v188
505	0		_aAntibody-drug conjugates -- Tumor-Infiltrating Lymphocytes as a Surrogate Biomarker for PD-L1 -- Immune checkpoint inhibitors -- Screening programs for breast cancer -- Transversal perspectives of integrative oncology care -- Assessment and response to neoadjuvant treatments -- Precision surgery for the treatment of breast cancer -- A precise approach for radiation therapy of breast cancer -- Fast mimicking diets and other innovative nutritional interventions to treat patients with breast cancer -- Endocrine resistance of breast cancer -- Innovative therapeutic approaches for patients with HER2- positive breast cancer -- Management of patients with breast cancer and brain metastasis -- New concepts in cardio-oncology -- Clinical utility, cost-effectiveness, and budgetary impact of next-generation sequencing in metastatic breast cancer -- ONCOLLEGE-001: The global landscape on the access to cancer medicines for breast cancer.
520			_aThis book focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters. Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management. The closing chapters deal with the challenges of low income countries of conducting research in the era of precision medicine forcancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-33602-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_Medicine_2023
999			_c402914 _d402914